Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5210MR)

This product GTTS-WQ5210MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5210MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15665MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ3063MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ4293MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ14409MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ10047MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ4852MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ195MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ4776MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BR3-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW